BERWYN, PA — Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) has announced that Matthew Barnes, the company’s senior director of portfolio management, will be presenting at the Outsourcing in Clinical Trials (OCT) Conference. The OCT Conference is a premier gathering for the clinical trial industry, attracting over 1,000 global leaders annually to exchange ideas and strategies for optimizing trial timelines and maintaining cost efficiency.
The conference serves as a critical platform for collaboration among biotech and pharmaceutical firms, clinical trial sponsors, medical device manufacturers, and solution providers, aimed at achieving advancements in clinical trial management and execution. Through its participation, Virpax underscores its commitment to contributing to industry-wide progress in clinical development.
Additionally, Virpax Pharmaceuticals celebrated its senior leaders, Dr. Sheila Mathias, Chief Scientific Officer, and Matthew Barnes, for their recent publications. The pair co-authored two articles featured in the DIA Global Forum and another in the Outsourcing in Clinical Trials Handbook 2025. These contributions reflect the company’s ongoing dedication to thought leadership in the biotechnology and pharmaceutical sectors.
Virpax continues to affirm its role as an influential voice in clinical trial innovation while advancing its own portfolio of therapeutic solutions.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.